EPISODE · Jun 29, 2026 · 18 MIN
PharmAla Biotech Holdings (MDMA): The World's Leading Clinical-Grade MDMA Supplier — and What's Next
from WTR Small-Cap Spotlight · host Water Tower Research
Send us Fan MailIn this special episode of the WTR Small Cap Spotlight Podcast, originally featured on WTR Healthcare Happenings, Nick Kadysh, Founding CEO and President of PharmAla Biotech Holdings (CSE: MDMA), joins host Tim Gerdeman and WTR Healthcare Analyst Robert Sassoon to discuss the company's positioning as a world-leading supplier of clinical-grade MDMA and its strategy for unlocking pipeline value through smart partnerships. Nick walks through two recently announced transactions: the formation of Restora Neurosciences, a 50/50 SPV to advance APA-01, a non-psychedelic neurology molecule targeting traumatic brain injury and stroke, and a term sheet granting Jupiter Neurosciences (NASDAQ: JUNS) exclusive US rights to lead asset ALA-002, valued at more than $100 million. He also explains why a focused, capital-efficient model matters for a seven-person company supporting 33 clinical trials worldwide.
Embed this episode
What this episode covers
Send us Fan Mail In this special episode of the WTR Small Cap Spotlight Podcast, originally featured on WTR Healthcare Happenings, Nick Kadysh, Founding CEO and President of PharmAla Biotech Holdings (CSE: MDMA), joins host Tim Gerdeman and WTR Healthcare Analyst Robert Sassoon to discuss the company's positioning as a world-leading supplier of clinical-grade MDMA and its strategy for unlocking pipeline value through smart partnerships. Nick walks through two recently announced transactions: ...
NOW PLAYING
PharmAla Biotech Holdings (MDMA): The World's Leading Clinical-Grade MDMA Supplier — and What's Next
No transcript for this episode yet
Similar Episodes
No similar episodes found.